Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597

Vicki Keedy, Wei Wang, Joan Schiller, Sunil Chada, Bonnie Slovis, Keith Coffee, John Worrell, Lyn A. Thet, David H. Johnson, David P. Carbone

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). Patients and Methods: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 × 109 viral particles (vp) per dose and escalated to a maximum of 2 × 1012 vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. Results: Twenty-five patients were treated at doses between 2 × 10 9 and 2 × 1012 vp. At 2 × 1012 vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 × 1011 vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. Conclusion: Ad-p53 can be administered safely by BAL at 5 × 1011 vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.

Original languageEnglish (US)
Pages (from-to)4166-4171
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number25
DOIs
StatePublished - 2008

Fingerprint

Bronchoalveolar Lavage
Adenoviridae
Carcinoma
Lung
Virion
Bronchiolo-Alveolar Adenocarcinoma
Maximum Tolerated Dose
p53 Genes
Sputum
Dyspnea
Respiration
Fever
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma : ECOG 6597. / Keedy, Vicki; Wang, Wei; Schiller, Joan; Chada, Sunil; Slovis, Bonnie; Coffee, Keith; Worrell, John; Thet, Lyn A.; Johnson, David H.; Carbone, David P.

In: Journal of Clinical Oncology, Vol. 26, No. 25, 2008, p. 4166-4171.

Research output: Contribution to journalArticle

Keedy, Vicki ; Wang, Wei ; Schiller, Joan ; Chada, Sunil ; Slovis, Bonnie ; Coffee, Keith ; Worrell, John ; Thet, Lyn A. ; Johnson, David H. ; Carbone, David P. / Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma : ECOG 6597. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 25. pp. 4166-4171.
@article{d42eab8c29404121a688538003d2e2aa,
title = "Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597",
abstract = "Purpose: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). Patients and Methods: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 × 109 viral particles (vp) per dose and escalated to a maximum of 2 × 1012 vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. Results: Twenty-five patients were treated at doses between 2 × 10 9 and 2 × 1012 vp. At 2 × 1012 vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 × 1011 vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. Conclusion: Ad-p53 can be administered safely by BAL at 5 × 1011 vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.",
author = "Vicki Keedy and Wei Wang and Joan Schiller and Sunil Chada and Bonnie Slovis and Keith Coffee and John Worrell and Thet, {Lyn A.} and Johnson, {David H.} and Carbone, {David P.}",
year = "2008",
doi = "10.1200/JCO.2007.15.6927",
language = "English (US)",
volume = "26",
pages = "4166--4171",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma

T2 - ECOG 6597

AU - Keedy, Vicki

AU - Wang, Wei

AU - Schiller, Joan

AU - Chada, Sunil

AU - Slovis, Bonnie

AU - Coffee, Keith

AU - Worrell, John

AU - Thet, Lyn A.

AU - Johnson, David H.

AU - Carbone, David P.

PY - 2008

Y1 - 2008

N2 - Purpose: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). Patients and Methods: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 × 109 viral particles (vp) per dose and escalated to a maximum of 2 × 1012 vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. Results: Twenty-five patients were treated at doses between 2 × 10 9 and 2 × 1012 vp. At 2 × 1012 vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 × 1011 vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. Conclusion: Ad-p53 can be administered safely by BAL at 5 × 1011 vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.

AB - Purpose: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). Patients and Methods: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 × 109 viral particles (vp) per dose and escalated to a maximum of 2 × 1012 vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. Results: Twenty-five patients were treated at doses between 2 × 10 9 and 2 × 1012 vp. At 2 × 1012 vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 × 1011 vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. Conclusion: Ad-p53 can be administered safely by BAL at 5 × 1011 vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.

UR - http://www.scopus.com/inward/record.url?scp=51649128840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649128840&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.6927

DO - 10.1200/JCO.2007.15.6927

M3 - Article

C2 - 18757331

AN - SCOPUS:51649128840

VL - 26

SP - 4166

EP - 4171

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -